Regeneron Pharmaceuticals Inc (REGN): Sanofi-Aventis Continues to Acquire Stock


Sanofi-Aventis, a large shareholder at Regeneron Pharmaceuticals Inc (NASDAQ:REGN) reported the purchase of 152,629 shares of common stock through twelve separate transactions, with unit prices ranging from $323.896 to $334.8098, on October 15, 2014. Sanofi-Aventis has been using this aggressive purchasing approach every month this year since January. Before Sanofi-Aventis acquisition spree, only 2010 have seen so much activity on the trading board, with the latest acquisition done by Director George L. Sing.

Andreas Halvorsen’s Viking Global is the largest shareholding institution (amongst those we track) at Regeneron Pharmaceuticals Inc (NASDAQ:REGN) with 2,963,456 shares of common stock, estimated to value $8.4 million, after reporting an 84% increment in its holding for the last filling period. Samuel Isaly’s Orbimed Advisors is another important institution, however its holding is considerably smaller, standing at 326,600 shares, worth $92 million.

Regeneron Pharmaceuticals Inc (NASDAQ:REGN) is an integrated biopharmaceutical company, which discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions.

Suggested Articles:

Richest Actors In the World

Most Expensive Boats In the World